February 1, 2021Diabetes Technology & Therapeutics

A 10% increase in TIR 70-180 mg/dL was associated with lower odds of CAN (OR 0.876, 95% CI 0.79-0.98), while a 10% increase in TAR >180 mg/dL was associated with higher odds of CAN (OR 1.141, 97.5% CI 1.01-1.29).

View Full Paper

Ask AI

Bookmark

Why the study?

Continuous glucose monitoring metrics are emerging indicators beyond HbA1c, but their associations with cardiovascular autonomic neuropathy in type 2 diabetes needed investigation.

Are continuous glucose monitoring-derived metrics associated with the presence and severity of cardiovascular autonomic neuropathy in outpatients with type 2 diabetes?

Population

284 outpatients with type 2 diabetes who underwent CGM and autonomic function tests

Comparison

Associations across CGM-derived TIR, hyperglycemia, and hypoglycemia metrics

Design

Cross-sectional study

Authors

MKMin Young Kim GKGyuri Kim JPJi Yun Park

Discussion

Member takes

Overview

Supports CGM-derived TIR for CAN evaluation in T2D; leaves open causality and need for prospective trials.

Structured PICO

Are continuous glucose monitoring-derived metrics associated with the presence and severity of cardiovascular autonomic neuropathy in outpatients with type 2 diabetes?

Population

284 outpatients with type 2 diabetes who underwent continuous glucose monitoring (CGM) for 3 or 6 days and autonomic function tests within 3 months.

Intervention

Continuous glucose monitoring (CGM)-derived metrics, specifically Time in Range (TIR) 70-180 mg/dL and Time Above Range (TAR) >180 mg/dL

Outcome

Presence of cardiovascular autonomic neuropathy (CAN), defined as an abnormal result in two or more parasympathetic tests, and severity of CANsurrogate

Higher time in range and lower time above range on continuous glucose monitoring are associated with a lower prevalence and severity of cardiovascular autonomic neuropathy in patients with type 2 diabetes.

Cite This Study

Kim et al. (2021) studied this question.

synapsesocial.com/papers/6a8539434edd3eca19cf240e https://doi.org/10.1089/dia.2020.0599

View Full Paper

Ask AI

Bookmark

February 1, 2021Diabetes Technology & Therapeutics

A 10% increase in TIR 70-180 mg/dL was associated with lower odds of CAN (OR 0.876, 95% CI 0.79-0.98), while a 10% increase in TAR >180 mg/dL was associated with higher odds of CAN (OR 1.141, 97.5% CI 1.01-1.29).

View Full Paper

Ask AI

Bookmark

Why the study?

Continuous glucose monitoring metrics are emerging indicators beyond HbA1c, but their associations with cardiovascular autonomic neuropathy in type 2 diabetes needed investigation.

Are continuous glucose monitoring-derived metrics associated with the presence and severity of cardiovascular autonomic neuropathy in outpatients with type 2 diabetes?

Population

284 outpatients with type 2 diabetes who underwent CGM and autonomic function tests

Comparison

Associations across CGM-derived TIR, hyperglycemia, and hypoglycemia metrics

Design

Cross-sectional study

Authors

MKMin Young Kim GKGyuri Kim JPJi Yun Park

Discussion

Member takes

Overview

Supports CGM-derived TIR for CAN evaluation in T2D; leaves open causality and need for prospective trials.

Structured PICO

Are continuous glucose monitoring-derived metrics associated with the presence and severity of cardiovascular autonomic neuropathy in outpatients with type 2 diabetes?

Population

284 outpatients with type 2 diabetes who underwent continuous glucose monitoring (CGM) for 3 or 6 days and autonomic function tests within 3 months.

Intervention

Continuous glucose monitoring (CGM)-derived metrics, specifically Time in Range (TIR) 70-180 mg/dL and Time Above Range (TAR) >180 mg/dL

Outcome

Presence of cardiovascular autonomic neuropathy (CAN), defined as an abnormal result in two or more parasympathetic tests, and severity of CANsurrogate

Cite This Study

Kim et al. (2021) studied this question.

synapsesocial.com/papers/6a8539434edd3eca19cf240e https://doi.org/10.1089/dia.2020.0599

View Full Paper

Ask AI

Bookmark